Cargando…

Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes

Encapsulation of Doxorubicin (Dox), a potent cytotoxic agent and immunogenic cell death inducer, in pegylated (Stealth) liposomes, is well known to have major pharmacologic advantages over treatment with free Dox. Reformulation of alendronate (Ald), a potent amino-bisphosphonate, by encapsulation in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gabizon, Alberto, Shmeeda, Hilary, Draper, Benjamin, Parente-Pereira, Ana, Maher, John, Carrascal-Miniño, Amaia, de Rosales, Rafael T. M., La-Beck, Ninh M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675201/ https://www.ncbi.nlm.nih.gov/pubmed/38004584 http://dx.doi.org/10.3390/pharmaceutics15112606

Ejemplares similares

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model
por: Islam, Md. Rakibul, et al.
Publicado: (2023)

In Vivo PET Tracking of (89)Zr-Labeled Vγ9Vδ2 T Cells to Mouse Xenograft Breast Tumors Activated with Liposomal Alendronate
por: Man, Francis, et al.
Publicado: (2019)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)

Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines
por: Edmonds, Scott, et al.
Publicado: (2016)

Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy
por: Gabizon, Alberto, et al.
Publicado: (2021)

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
por: Golan, Talia, et al.
Publicado: (2015)

Synergy between liposomal zoledronic acid and γδ T-cells in the treatment of epithelial ovarian cancer
por: Pereira, Ana Catarina Parente, et al.
Publicado: (2013)

In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice
por: Hodgins, Naomi O., et al.
Publicado: (2016)

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience
por: Tahover, Esther, et al.
Publicado: (2018)

Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts
por: Christensen, Esben, et al.
Publicado: (2018)

Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma
por: Nguyen, Tuyen Duong Thanh, et al.
Publicado: (2016)

Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery
por: La-Beck, Ninh M., et al.
Publicado: (2019)

Harnessing RNAi nanomedicine for precision therapy
por: Peer, Dan
Publicado: (2014)

A kit formulation for the preparation of [(89)Zr]Zr(oxinate)(4) for PET cell tracking: White blood cell labelling and comparison with [(111)In]In(oxinate)(3)
por: Man, Francis, et al.
Publicado: (2020)

Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
por: Sun, Bo, et al.
Publicado: (2020)

Harnessing Protein Corona for Biomimetic Nanomedicine Design
por: Chen, Zhidong, et al.
Publicado: (2022)

PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)

Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck
por: Xu, Qiang, et al.
Publicado: (2020)

Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore
por: Gawne, Peter, et al.
Publicado: (2018)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration
por: Sangrà, Marc, et al.
Publicado: (2017)

Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics
por: Van Herck, Simon, et al.
Publicado: (2020)

Organ Biodistribution of Radiolabelled γδ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models
por: Wang, Julie T-W., et al.
Publicado: (2020)

Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment
por: Plan Sangnier, Anouchka, et al.
Publicado: (2018)

Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases
por: Carney, Christine P., et al.
Publicado: (2021)

Power in Numbers: Harnessing Combinatorial and Integrated Screens to Advance Nanomedicine
por: Boehnke, Natalie, et al.
Publicado: (2021)

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy
por: La-Beck, Ninh M., et al.
Publicado: (2017)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes
por: Miatmoko, Andang, et al.
Publicado: (2021)

Conventional and PEGylated Liposomes as Vehicles of Copaifera sabulicola
por: Blanco, Ian M. R., et al.
Publicado: (2023)

Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine
por: Man, Francis, et al.
Publicado: (2019)

Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics()
por: Bonavida, Benjamin, et al.
Publicado: (2015)

Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy
por: Chen, Shanshan, et al.
Publicado: (2023)

Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs
por: Tang, Huan, et al.
Publicado: (2022)

PEGylated Paclitaxel Nanomedicine Meets 3D Confinement: Cytotoxicity and Cell Behaviors
por: Lin, Wenhai, et al.
Publicado: (2023)

Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy
por: Rommasi, Foad, et al.
Publicado: (2021)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h9jsrd9o8fjjo162m4qnk2rqg3